Showing 1901-1910 of 2038 results for "".
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- Gil Kliman, MD, and Tom Frinzi Appointed to STAAR Surgical Board of Directorshttps://modernod.com/news/gil-kliman-md-and-tom-frinzi-appointed-to-staar-surgical-board-of-directors/2477846/Staar Surgical announced the appointment of Gilbert H. Kliman, MD, Managing Partner, InterWest Partners, and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its board of directors, effective June 1, 2020. The appointment of Dr. Kliman and Mr. Frinzi brings
- In-Person ESCRS and Euretina Meetings Cancelled; Virtual Meetings Plannedhttps://modernod.com/news/escrs-and-euretina-meetings-cancelled-virtual-meetings-planned/2477843/Due to the COVID-19 pandemic, the in-person ESCRS and Euretina meetings, scheduled to take place in Amsterdam in October, have been cancelled. Instead, the 38th Congress of the ESCRS and the 20th Euretina Congress will be held in a virtual format. In a joint letter to their memberships, ES
- Sonoma Pharmaceuticals Announces New CE Marking for Microdacyn60 Eye Carehttps://modernod.com/news/sonoma-pharmaceuticals-announces-new-ce-marking-for-microdacyn60-eye-care/2477833/Sonoma Pharmaceuticals has announced that it received a new CE Marking for its Microdacyn60 eye care based on Sonoma’s patented Microcyn Technology. The formulation, marketed in the United States as Acuicyn Antimicrobial Eyelid and Eyelash Hygiene solution, is a safe and efficac
- Mynosys Changes Name to Centricity Vision; Names New Leadership Teamhttps://modernod.com/news/mynosys-changes-name-to-centricity-vision-names-new-leadership-team/2477834/Centricity Vision, formerly known as Mynosys Cellular Devices, announced a new executive leadership team, along with a new company name. Centricity Vision reflects the company’s core competency, embodied by its Zepto Precision Cataract Surgery Platform, in creating precise, consistent, vis
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope
- Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapieshttps://modernod.com/news/regeneron-ceo-manufacturing-not-up-to-snuff-for-covid-19-vaccines-therapies/2477753/Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman i
- Alnylam, Vir to Advance Experimental RNAi Therapeutic VIR-2703 as Potential COVID-19 Treatmenthttps://modernod.com/news/alnylam-vir-to-advance-experimental-rnai-therapeutic-vir-2703-as-potential-covid-19-treatment/2477702/Alnylam Pharmaceuticals and Vir Biotechnology announced that they plan to develop VIR-2703, an investigational RNAi therapeutic targeting the SARS-CoV-2 genome as an inhalational formulation for the potential treatment or prevention of COVID-19. “To our knowledge, this is one of the
- AAO Expands Partnership with Verana Health to Include EHR Data Integration and MIPS Reporting for the IRIS Registryhttps://modernod.com/news/aao-expands-partnership-with-verana-health-to-include-ehr-data-integration-and-mips-reporting-for-the-iris-registry/2477671/The American Academy of Ophthalmology (AAO) announced that Verana Health, the data curation and analytics partner of the American Academy of Ophthalmology IRIS Registry (Intelligent Research In Sight), will serve as the end-to-end data and technology partner for the IRIS Registry moving forward.
- FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside Of the Hospital Settinghttps://modernod.com/news/fda-cautions-against-use-of-hydroxychloroquine-or-chloroquine-for-covid-19-outside-of-the-hospital-setting/2477649/In a safety communication posted on Friday, the FDA warned consumers against taking malaria drugs chloroquine and hydroxychloroquine to treat COVID-19 outside a hospital or formal clinical trial setting. The updated guidance comes after reports of serious heart rhythm problems in patients with CO